Decibel Therapeutics (DBTX) Income Statement (2021 - 2023)
Income Statement report data from Mar 31, 2021 to Jun 30, 2023 for Decibel Therapeutics (DBTX).
Reported currency: USD
| Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | ||||||||||
Research And Development | 13M (+61.79%) | 7.93M (-31.58%) | 12M (+15.55%) | 10M (-10.77%) | 11M (+50.47%) | 7.47M (-6.39%) | 7.98M (-11.53%) | 9.02M (+32.06%) | 6.83M (+13.46%) | 6.02M |
Selling General And Administrative | 6.21M (+0.32%) | 6.19M (+26.58%) | 4.89M (-22.63%) | 6.32M (+7.85%) | 5.86M (-10.53%) | 6.55M (+33.13%) | 4.92M (-13.38%) | 5.68M (+15.92%) | 4.90M (+0.41%) | 4.88M |
Operating Expenses | 19M (+34.84%) | 14M (-14.37%) | 16M (+0.86%) | 16M (-4.39%) | 17M (+21.97%) | 14M (+8.68%) | 13M (-12.24%) | 15M (+25.32%) | 12M (+7.61%) | 11M |
Operating Income | ||||||||||
Operating Income | -19.04M (+34.84%) | -14.12M (-14.37%) | -16.49M (+0.86%) | -16.35M (-4.39%) | -17.10M (+21.97%) | -14.02M (+8.68%) | -12.90M (-12.24%) | -14.70M (+25.32%) | -11.73M (+7.61%) | -10.90M |
EBITDA | -19.07M (+35.06%) | -14.12M (-13.69%) | -16.36M (+0.06%) | -16.35M (-1.03%) | -16.52M (+23.75%) | -13.35M (+8.89%) | -12.26M (-12.80%) | -14.06M (+26.44%) | -11.12M (+7.03%) | -10.39M |
Other Income / Expenses | ||||||||||
Interest Income | 980K (+11.36%) | 880K (+33.33%) | 660K (+78.38%) | 370K (+270.00%) | 100K (+66.67%) | 60K (+20.00%) | 50K (+66.67%) | 30K (-62.50%) | 80K (+166.67%) | 30K |
Net Interest Income | 980K (+11.36%) | 880K (+33.33%) | 660K (+78.38%) | 370K (+270.00%) | 100K (+66.67%) | 60K (+20.00%) | 50K (+66.67%) | 30K (-62.50%) | 80K (+166.67%) | 30K |
Net Income | ||||||||||
Income Before Tax | -18.07M (+36.48%) | -13.24M (-16.36%) | -15.83M (-0.88%) | -15.97M (-6.11%) | -17.01M (+21.85%) | -13.96M (+8.72%) | -12.84M (-12.47%) | -14.67M (+25.92%) | -11.65M (+7.18%) | -10.87M |
Income Tax Expense | 80K (+33.33%) | 60K (-45.45%) | 110K (+266.67%) | 30K (-25.00%) | 40K (-33.33%) | 60K (-14.29%) | 70K (-95.95%) | 1.73M | - | - |
Net Income From Continuing Operations | -18.14M (+36.39%) | -13.30M (-16.56%) | -15.94M (-0.38%) | -16.00M (-6.16%) | -17.05M (+21.61%) | -14.02M (+8.68%) | -12.90M (-21.34%) | -16.40M (+40.77%) | -11.65M (+7.18%) | -10.87M |
Net Income | -18.14M (+36.39%) | -13.30M (-16.56%) | -15.94M (-0.38%) | -16.00M (-6.16%) | -17.05M (+21.61%) | -14.02M (+8.68%) | -12.90M (-21.34%) | -16.40M (+40.77%) | -11.65M (+7.18%) | -10.87M |